LLY - Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS Dementia Prospect | Benzinga
On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. (NYSE:LLY).
QurAlis has granted Lilly global rights to develop and commercialize QRL-204, a splice-switching antisense oligonucleotide (ASO) designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases.
Under the terms of the agreement, QurAlis granted Lilly an exclusive, worldwide license to develop and commercialize QRL-204 and other UNC13A-targeting compounds in exchange for an upfront payment of $45 million to QurAlis, plus an additional equity investment.
QurAlis is also eligible for future milestone payments of up to $577 million and tiered ...